Eltrombopag

What is Eltrombopag?

Eltrombopag is a small-molecule, oral thrombopoietin (TPO) receptor agonist belonging to the ATC classification B06 (blood and blood-forming organs agents). It is used primarily to treat patients with low platelet counts, a condition known as thrombocytopenia. The medication works by stimulating the bone marrow to produce more platelets, thereby reducing the risk of bleeding complications in patients with various hematologic disorders.

Eltrombopag was developed and first approved by the FDA in 2008 under the brand name Promacta for the treatment of chronic immune thrombocytopenia (ITP). Since its introduction, it has expanded to additional clinical indications including hepatitis C virus (HCV)-associated thrombocytopenia and aplastic anemia. The drug represents a significant advancement in managing platelet disorders where traditional treatments may be ineffective or poorly tolerated.

As a first-generation TPO receptor agonist, Eltrombopag has become a cornerstone therapy in hematology and hepatology practices. Its oral formulation makes it convenient for long-term management compared to intravenous alternatives. The medication is available in tablet form with varying strengths to allow personalized dosing based on patient response and tolerability.

⚙️ Mechanism of Action

Eltrombopag exerts its therapeutic effects by binding to the thrombopoietin (TPO) receptor on the surface of hematopoietic stem cells and megakaryocytes in the bone marrow. This non-peptide agonist mimics the action of endogenous TPO, the primary physiologic regulator of platelet production. By activating the TPO receptor (also known as c-Mpl), Eltrombopag stimulates proliferation and differentiation of megakaryocytes, leading to increased production and release of platelets into the bloodstream.

• Binds directly to the transmembrane domain of the thrombopoietin receptor (c-Mpl), causing conformational changes that activate intracellular signaling pathways
• Stimulates JAK2/STAT3 and PI3K/Akt signaling cascades within megakaryocytes, promoting cell survival, proliferation, and maturation
• Increases both the number and maturity of megakaryocytes in the bone marrow microenvironment
• Enhances platelet production without directly affecting platelet survival or function, maintaining normal hemostatic properties
• Demonstrates selectivity for human TPO receptors with minimal off-target effects on other hematopoietic lineages at therapeutic concentrations

🏥 Medical Uses & Indications

Eltrombopag has multiple approved and investigational uses in clinical hematology and hepatology. As a versatile TPO receptor agonist, it addresses the fundamental pathophysiology of thrombocytopenia across different disease etiologies. The medication has demonstrated efficacy in both primary immune-mediated disorders and secondary thrombocytopenia associated with systemic conditions, making it a valuable therapeutic option for hematologists managing complex platelet disorders.

Primary Indications

• Chronic Immune Thrombocytopenia (ITP): Treatment of adult patients with ITP who have insufficient response to corticosteroids, immunoglobulins, or splenectomy
• Hepatitis C Virus (HCV)-Associated Thrombocytopenia: Enabling HCV treatment in patients with baseline thrombocytopenia that would otherwise preclude antiviral therapy
• Aplastic Anemia: Used in patients with aplastic anemia who have an insufficient response to immunosuppressive therapy or are unsuitable for such treatment
• Chemotherapy-Induced Thrombocytopenia (CIT): Prevention and management of low platelet counts in patients receiving chemotherapy for solid tumors
• Immune Thrombocytopenia in Chronic Hepatitis B: Treatment of thrombocytopenia in patients with chronic hepatitis B infection
• Thrombocytopenia Associated with Myelodysplastic Syndrome (MDS): Management of thrombocytopenia in patients with MDS to reduce transfusion requirements

Secondary / Off-label Uses

• Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)-Associated Thrombocytopenia: Experimental use to promote platelet recovery post-transplant
• Drug-Induced Thrombocytopenia: Management of thrombocytopenia secondary to medications such as antiretrovirals or certain antimicrobials
• Systemic Lupus Erythematosus (SLE)-Associated Thrombocytopenia: Off-label use in SLE patients with refractory immune-mediated platelet destruction

💊 Dosage & Administration

Eltrombopag is administered orally as tablets available in multiple strengths (12.5 mg, 25 mg, 50 mg, and 75 mg). Dosing is individualized based on patient response, with the goal of achieving and maintaining a safe platelet count while minimizing exposure to the medication. Initial doses typically range from 25-50 mg daily, with adjustments made at 1-2 week intervals based on platelet response and tolerability. All doses should be taken on an empty stomach, at least 2 hours before or 4 hours after ingestion of food, dairy products, or calcium-containing supplements, as these significantly reduce drug absorption.

Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Regular monitoring of platelet counts and liver function is essential during treatment with Eltrombopag. Dose adjustments should be made cautiously to maintain platelet counts in the target range (typically 50,000-200,000/μL for most indications) without overtreatment that could increase thrombotic risk.

⚠️ Side Effects

Common Side Effects (>10% of patients)

• Headache: Often mild to moderate, occurring in approximately 25% of treated patients
• Nausea and Vomiting: Gastrointestinal upset affecting 10-20% of patients, typically manageable with timing adjustments
• Diarrhea: Occurring in 10-15% of patients, usually self-limiting with continued therapy
• Fatigue and Asthenia: General weakness and tiredness reported in 10-12% of patients
• Upper Respiratory Tract Infections: Increased susceptibility in approximately 10% of patients
• Rhinitis and Sinusitis: Upper respiratory inflammation occurring in 10-15% of the treatment population

Less Common Side Effects (1-10%)

• Elevated Liver Transaminases: Mild to moderate increases in ALT and AST (2-8% of patients), requiring monitoring
• Cataracts: Lens opacity development reported in 1-2% of patients, particularly with prolonged use
• Abdominal Pain and Dyspepsia: Gastrointestinal discomfort in 3-5% of treated patients
• Myalgia and Arthralgia: Muscle and joint pain occurring in 2-4% of patients
• Insomnia and Sleep Disturbances: Sleep-related adverse events in 1-3% of patients

Rare but Serious Side Effects

• Thromboembolic Events: Risk of blood clots including deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly in patients with pre-existing risk factors or those with platelet counts >400,000/μL
• Hepatotoxicity and Liver Cirrhosis Progression: Severe hepatic injury and accelerated cirrhosis development in patients with chronic hepatic disease, with reported cases of liver failure
• Bone Marrow Fibrosis: Rare progressive fibrosis of bone marrow leading to irreversible thrombocytopenia and myelodysplasia

🔄 Drug Interactions

Eltrombopag undergoes hepatic metabolism via UDP-glucuronosyltransferase (UGT1A1) and CYP2C8, and is a substrate for organic anion transporter proteins (OAT1 and OAT3). The medication has potential for significant drug interactions, particularly with medications that inhibit or induce these pathways, or those that interfere with its absorption through chelation. Careful monitoring and dose adjustments may be necessary when Eltrombopag is co-administered with certain medications.

• Calcium Supplements and Antacids: Calcium, magnesium, aluminum, and iron-containing products bind Eltrombopag in the gastrointestinal tract, reducing absorption by up to 70%; administration must be separated by at least 2 hours
• Warfarin: Potential for increased anticoagulant effect and bleeding risk; INR monitoring is recommended as Eltrombopag may displace warfarin from protein binding
• Potent CYP2C8 Inhibitors (Gemfibrozil, Trimethoprim): These medications inhibit Eltrombopag metabolism, increasing plasma concentrations and potentially causing platelet count elevations; dose reduction of Eltrombopag may be necessary
• Organic Anion Transporter Inhibitors (Probenecid, Cimetidine): These drugs inhibit renal clearance of Eltrombopag, increasing systemic exposure and risk of adverse effects
• Immunosuppressive Agents: Potential for additive myelosuppression when combined with other immunosuppressive or cytotoxic medications used in aplastic anemia treatment
• Directly Acting Antivirals (DAAs): Minor interaction potential; increased monitoring of platelet counts recommended in HCV patients receiving concurrent antiviral therapy

🚫 Contraindications & Warnings

• Hypersensitivity: Eltrombopag is contraindicated in patients with known hypersensitivity to the drug or any of its inactive components
• Hepatic Impairment: Use with extreme caution in patients with pre-existing liver disease, as Eltrombopag undergoes hepatic metabolism and may accelerate cirrhosis progression; liver function monitoring is mandatory
• Thrombotic Disorders and Hypercoagulability: Contraindicated in patients with a personal history of thromboembolism or those with significantly elevated baseline thrombotic risk, as increasing platelet counts may precipitate clotting
• Uncontrolled Hypertension: Eltrombopag should be avoided in patients with severe uncontrolled hypertension, as there is a potential for blood pressure elevation
• Myelodysplastic Syndrome with Cytopenia: Use with caution as Eltrombopag may potentially promote disease progression and transformation to acute leukemia in MDS patients
• Pregnancy and Lactation: Insufficient safety data for use in pregnant women; Eltrombopag is classified as Pregnancy Category C; excretion in breast milk unknown, so breastfeeding is not recommended during treatment

Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. The content provided does not replace professional medical advice, diagnosis, or treatment. Individual patient circumstances vary significantly, and therapeutic decisions must be made by qualified healthcare providers with full knowledge of the patient's medical history and current clinical status.

❓ Frequently Asked Questions

Is Eltrombopag safe for long-term use?

Eltrombopag can be used for long-term management of chronic thrombocytopenia, and many patients have been treated successfully for years. However, long-term safety requires careful monitoring, including regular assessment of platelet counts, liver function tests, and surveillance for signs of bone marrow fibrosis. The medication should be used at the lowest effective dose to minimize cumulative exposure. Periodic assessment of the need for continued therapy is recommended, and some patients may achieve sustained remission after discontinuation.

Can Eltrombopag be taken with food?

No, Eltrombopag must be taken on an empty stomach for optimal absorption. Food, particularly dairy products, calcium supplements, iron supplements, and antacids, significantly reduce the drug's bioavailability. The medication should be taken at least 2 hours before meals or 4 hours after eating. This strict dietary restriction is important to ensure adequate drug levels and therapeutic efficacy. Taking Eltrombopag with food can reduce its absorption by up to 70%, potentially leading to subtherapeutic drug concentrations.

What should I do if I miss a dose?

If you miss a dose of Eltrombopag, take it as soon as you remember, provided you can do so on an empty stomach. If your next scheduled dose is approaching (within a few hours), skip the missed dose and resume your normal dosing schedule. Do not double doses to compensate for a missed dose, as this could result in excessive platelet elevation and increase thrombotic risk. Maintaining a regular dosing schedule is important for stable platelet count management, so setting reminders may help improve medication adherence.